TrialInvestigational new drugs2023

Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE).

Kun Qian et al.PubMed ↗Publisher ↗

No numbers read from the abstract.